以利妥昔单抗作为一线免疫抑制剂成功治疗高安动脉炎。
Successful treatment of Takayasu arteritis with rituximab as a first-line immunosuppressant.
作者信息
O'Connor Mortimer B, O'Donovan Neil, Bond Ursula, Phelan Mark J
机构信息
Department of Medicine, Mercy University Hospital, Cork, Ireland.
Department of Rheumatology, South Infirmary Victoria University Hospital, Cork, Ireland.
出版信息
BMJ Case Rep. 2017 Jan 10;2017:bcr2016217313. doi: 10.1136/bcr-2016-217313.
Abstract
Takayasu arteritis is a rare large vessel vasculitis which has traditionally been treated with high-dose steroids. There have been a small number of publications where biological agents have been used to manage refractory cases. To the authors knowledge, there are no publications using biological agents in combination with steroids as a first-line treatment in Takayasu arteritis. In this publication, we document the case of Takayasu arteritis, in a 39-year-old woman, where rituximab was used in combination with steroids as a first-line agent in the setting of poorly controlled bipolar affective disorder.
摘要
高安动脉炎是一种罕见的大血管血管炎，传统上采用大剂量类固醇进行治疗。已有少数出版物报道使用生物制剂治疗难治性病例。据作者所知，尚无关于在高安动脉炎中使用生物制剂联合类固醇作为一线治疗的出版物。在本出版物中，我们记录了一名39岁女性高安动脉炎的病例，该患者在双相情感障碍控制不佳的情况下，使用利妥昔单抗联合类固醇作为一线药物治疗。
相似文献
1
Successful treatment of Takayasu arteritis with rituximab as a first-line immunosuppressant.
BMJ Case Rep. 2017 Jan 10;2017:bcr2016217313. doi: 10.1136/bcr-2016-217313.
2
Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: Single centre experience from a large tertiary care teaching hospital in Southern India.
Semin Arthritis Rheum. 2018 Apr;47(5):718-726. doi: 10.1016/j.semarthrit.2017.09.014. Epub 2017 Sep 30.
3
Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S114-29. Epub 2012 May 11.
4
Takayasu arteritis a cause of hypertensive disorder of pregnancy: a case report.
J Med Case Rep. 2018 Jan 17;12(1):12. doi: 10.1186/s13256-017-1534-6.
5
Refractory Takayasu arteritis successfully treated with rituximab: case-based review.
Rheumatol Int. 2019 Nov;39(11):1989-1994. doi: 10.1007/s00296-019-04390-w. Epub 2019 Aug 6.
6
Current Diagnosis and Management of Takayasu Arteritis.
Int Heart J. 2023;64(4):519-534. doi: 10.1536/ihj.23-195.
7
Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases.
Ann Intern Med. 1999 Mar 2;130(5):422-6. doi: 10.7326/0003-4819-130-5-199903020-00013.
8
Update on Takayasu arteritis: Year in review 2024.
Int J Rheum Dis. 2024 Sep;27(9):e15314. doi: 10.1111/1756-185X.15314.
9
Two Takayasu arteritis patients successfully treated with rituximab.
Clin Rheumatol. 2014 Aug;33(8):1183-4. doi: 10.1007/s10067-014-2506-5. Epub 2014 Jan 31.
10
Tocilizumab treatment in childhood Takayasu arteritis: Case series of four patients and systematic review of the literature.
Semin Arthritis Rheum. 2017 Feb;46(4):529-535. doi: 10.1016/j.semarthrit.2016.07.012. Epub 2016 Jul 26.
引用本文的文献
1
A Glimpse into Humoral Response and Related Therapeutic Approaches of Takayasu's Arteritis.
Int J Mol Sci. 2024 Jun 13;25(12):6528. doi: 10.3390/ijms25126528.
2
Decreased Absolute Number of Circulating Regulatory T Cells in Patients With Takayasu's Arteritis.
Front Immunol. 2021 Dec 23;12:768244. doi: 10.3389/fimmu.2021.768244. eCollection 2021.
3
Refractory Takayasu arteritis successfully treated with rituximab: case-based review.
Rheumatol Int. 2019 Nov;39(11):1989-1994. doi: 10.1007/s00296-019-04390-w. Epub 2019 Aug 6.
4
CSI position statement on management of heart failure in India.
Indian Heart J. 2018 Jul;70 Suppl 1(Suppl 1):S1-S72. doi: 10.1016/j.ihj.2018.05.003. Epub 2018 Jun 8.
本文引用的文献
1
Two Takayasu arteritis patients successfully treated with rituximab.
Clin Rheumatol. 2014 Aug;33(8):1183-4. doi: 10.1007/s10067-014-2506-5. Epub 2014 Jan 31.
2
Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients.
Mayo Clin Proc. 2013 Aug;88(8):822-30. doi: 10.1016/j.mayocp.2013.04.025. Epub 2013 Jul 10.
3
Remission achieved in refractory advanced takayasu arteritis using rituximab.
Case Rep Rheumatol. 2012;2012:406963. doi: 10.1155/2012/406963. Epub 2012 Oct 10.
4
Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup.
Arthritis Care Res (Hoboken). 2012 Jul;64(7):1079-83. doi: 10.1002/acr.21636.
5
Tocilizumab: a novel therapy for patients with large-vessel vasculitis.
Rheumatology (Oxford). 2012 Jan;51(1):151-6. doi: 10.1093/rheumatology/ker296. Epub 2011 Nov 10.
6
Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab.
Ann Rheum Dis. 2012 Jan;71(1):75-9. doi: 10.1136/ard.2011.153007. Epub 2011 Sep 27.
7
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
N Engl J Med. 2010 Jul 15;363(3):211-20. doi: 10.1056/NEJMoa0909169.
8
The epidemiology of Takayasu arteritis in the UK.
Rheumatology (Oxford). 2009 Aug;48(8):1008-11. doi: 10.1093/rheumatology/kep153. Epub 2009 Jun 19.
9
Difficulties in diagnosing Takayasu's arteritis and the benefits of modern day imaging.
Ir J Med Sci. 2009 Sep;178(3):385-7. doi: 10.1007/s11845-009-0290-z. Epub 2009 Feb 7.
10
Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
Clin Rev Allergy Immunol. 2008 Feb;34(1):124-8. doi: 10.1007/s12016-007-8028-z.
Zotero 插件